MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients

Kai Doberstein*, Nico Steinmeyer, Ann Kathrin Hartmetz, Wolfgang Eberhardt, Michel Mittelbronn, Patrick N. Harter, Eva Juengel, Roman Blaheta, Josef Pfeilschifter, Paul Gutwein

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

81 Citations (Scopus)

Abstract

A disintegrin and metalloproteinase 17 (ADAM17) is a metalloprotease that is overexpressed in many cancer types, including renal cancers. However, the regulatory mechanisms of ADAM17 in cancer development and progression are poorly understood. In the present work, we provide evidence using overexpression and inhibition of microRNA 145 (miR-145) that miR-145 negatively regulates ADAM17 expression. Furthermore, we show that ADAM17 negatively regulates miR-145 through tumor necrosis factor-α, resulting in a reciprocal negative feedback loop. In this study, the expression of ADAM17 and miR-145 correlated negatively in renal cancer tumor tissues and cell lines, suggesting an important regulatory mechanism. Additionally, we showed that the regulation of ADAM17 is partly involved in the effects of miR-145 on proliferation and migration, whereas no involvement in chemosensitivity was observed. Importantly, in the healthy kidney, miR-145 was detected in different cell types including tubular cells, which are considered the origin of renal cancer. In renal cancer cell lines,miR-145 expression was strongly suppressed by methylation. In summary, miR-145 is downregulated in renal cancer patients, which leads to the up-regulation of ADAM17 in renal cancer. Importantly, miR-145 and ADAM17 are regulated in a reciprocal negative feedback loop.

Original languageEnglish
Pages (from-to)218-230
Number of pages13
JournalNeoplasia
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients'. Together they form a unique fingerprint.

Cite this